http://orcid.org/0000-0001-8352-6136
Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Chuankun Wang & Lizhe Qu. (2022) The anti-fibrotic agent nintedanib protects chondrocytes against tumor necrosis factor-ɑ (TNF-ɑ)-induced extracellular matrix degradation. Bioengineered 13:3, pages 5318-5329.
Read now
Read now
Shigeki Makino. (2021) Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Modern Rheumatology 31:1, pages 13-19.
Read now
Read now
Masataka Kuwana, Takashi Ogura, Shigeki Makino, Sakae Homma, Yasuhiro Kondoh, Aiko Saito, Hiroyuki Ugai, Martina Gahlemann, Kazuhiko Takehara & Arata Azuma. (2021) Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Modern Rheumatology 31:1, pages 141-150.
Read now
Read now
Francesco Benvenuti, Elisabetta Zanatta, Jérôme Avouac, Ulf Müller-Ladner, Franco Cozzi, Anna-Maria Hoffmann-Vold, Armando Gabrielli, Oliver Distler, Marco Matucci-Cerinic, Yannick Allanore & Andrea Doria. (2020) The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology 16:11, pages 1065-1074.
Read now
Read now
Articles from other publishers (22)
Wenxin Luo, Yilin Gu, Siyu Fu, Jiaxing Wang, Jifa Zhang & Yuxi Wang. (2023) Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways. European Journal of Medicinal Chemistry 260, pages 115762.
Crossref
Crossref
Marko Barešić, Srđan Novak, Dijana Perković, Boris Karanović, Filip Mirić, Mislav Radić & Branimir Anić. (2023) Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study. Clinical Rheumatology 42:10, pages 2897-2903.
Crossref
Crossref
Mitali Patel, Sneha Karampuri, Vrushti Kansara & Bhavin Vyas. (2023) Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations. Journal of Drug Delivery Science and Technology, pages 104716.
Crossref
Crossref
Sofie Falkenløve Madsen, Jannie Marie Bülow Sand, Pernille Juhl, Morten Karsdal, Christian S. Thudium, Anne Sofie Siebuhr & Anne-Christine Bay-Jensen. (2023) Fibroblasts are not just fibroblasts: clear differences between dermal and pulmonary fibroblasts’ response to fibrotic growth factors. Scientific Reports 13:1.
Crossref
Crossref
Hiraku Kokubu, Saki Takeuchi, Takahisa Tozawa, Satoko Hisada, Yoshihiro Yamada, Yumi Itoh & Masanari Kodera. (2023) Assessing prognostic factors correlating with response to nintedanib for connective tissue disease‐associated interstitial lung disease: A real‐world single‐center study. International Journal of Rheumatic Diseases 26:4, pages 682-688.
Crossref
Crossref
Frank Silva Bezerra, Manuella Lanzetti, Renata Tiscoski Nesi, Akinori Cardozo Nagato, Cyntia Pecli e Silva, Emanuel Kennedy-Feitosa, Adriana Correa Melo, Isabella Cattani-Cavalieri, Luís Cristóvão Porto & Samuel Santos Valenca. (2023) Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries. Antioxidants 12:3, pages 548.
Crossref
Crossref
Suhee Kim, Hee Jin Park & Sang-Il Lee. (2022) The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential. International Journal of Molecular Sciences 23:24, pages 16154.
Crossref
Crossref
Savino Sciascia, Martina Cozzi, Alice Barinotti, Massimo Radin, Irene Cecchi, Roberta Fenoglio, Daniele Mancardi, Georgia Wilson Jones, Daniela Rossi & Dario Roccatello. (2022) Renal Fibrosis in Lupus Nephritis. International Journal of Molecular Sciences 23:22, pages 14317.
Crossref
Crossref
Sylvia M. Nikkho, Manuel J. Richter, Eric Shen, Steven H. Abman, Katerina Antoniou, Jonathan Chung, Peter Fernandes, Paul Hassoun, Howard M. Lazarus, Horst Olschewski, Lucilla Piccari, Mitchell Psotka, Rajan Saggar, Oksana A. Shlobin, Norman Stockbridge, Patrizio Vitulo, Carmine Dario Vizza, Stephen J. Wort & Steven D. Nathan. (2022) Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension. Pulmonary Circulation 12:3.
Crossref
Crossref
Markus Bredemeier. (2022) Additional points to consider before incorporating the Food and Drug Administration–approved therapies for systemic sclerosis–associated interstitial lung disease: comment on the article by Khanna et al. Arthritis & Rheumatology 74:4, pages 733-734.
Crossref
Crossref
Rengul Cetin-Atalay, Deniz Cansen Kahraman, Esra Nalbat, Ahmet Sureyya Rifaioglu, Ahmet Atakan, Ataberk Donmez, Heval Atas, M. Volkan Atalay, Aybar C. Acar & Tunca Doğan. (2021) Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools. Journal of Gastrointestinal Cancer 52:4, pages 1266-1276.
Crossref
Crossref
Yoshikazu Inoue, Takafumi Suda, Hideya Kitamura, Masaki Okamoto, Arata Azuma, Naohiko Inase, Masataka Kuwana, Shigeki Makino, Yasuhiko Nishioka, Takashi Ogura, Ayako Takizawa, Hiroyuki Ugai, Susanne Stowasser, Rozsa Schlenker-Herceg & Tsutomu Takeuchi. (2021) Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine 187, pages 106574.
Crossref
Crossref
Francesca Ravanetti, Erica Ferrini, Luisa Ragionieri, Zahra Khalajzeyqami, Maria Nicastro, Yanto Ridwan, Alex Kleinjan, Gino Villetti, Andrea Grandi & Franco Fabio Stellari. (2021) SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib. Scientific Reports 11:1.
Crossref
Crossref
Yelyzaveta Yehudina, Svitlana Trypilka & Anna Isayeva. (2021) Clinical Puzzles and Decision-Making in Antisynthetase Syndrome. Cureus.
Crossref
Crossref
Michael Mahler, Grace Kim, Fabrece Roup, Chelsea Bentow, Nicole Fabien, David Goncalves, Boaz Palterer, Marvin J. Fritzler & Danilo Villalta. (2021) Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies. Immunologic Research 69:3, pages 239-248.
Crossref
Crossref
David Roofeh, Alain Lescoat & Dinesh Khanna. (2021) Treatment for systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology 33:3, pages 240-248.
Crossref
Crossref
Fabian A. Mendoza, Sonsoles Piera-Velazquez & Sergio A. Jimenez. (2021) Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Translational Research 231, pages 139-158.
Crossref
Crossref
Andrea De Pieri, Benjamin D. Korman, Astrid Jüngel & Karin Wuertz‐Kozak. (2021) Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. Advanced Biology 5:4.
Crossref
Crossref
Junyu Liang, Heng Cao, Yang Yang, Yini Ke, Ye Yu, Chuanyin Sun, Lihuan Yue & Jin Lin. (2021) Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Frontiers in Medicine 8.
Crossref
Crossref
Ebuka-Olisaemeka Nwafor, Peng Lu, Yiting Liu, Hui Peng, Huan Qin, Kuibin Zhang, Zhe Ma, Bin Xing, Yukun Zhang, Jiawei Li & Zhidong Liu. (2021) Active Components from Traditional Herbal Medicine for the Potential Therapeutics of Idiopathic Pulmonary Fibrosis: A Systemic Review. The American Journal of Chinese Medicine 49:05, pages 1093-1114.
Crossref
Crossref
Afua Kunadu, Shehabaldin Alqalyoobi, Robert C. Frere & Ogugua Ndili Obi. (2021) Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib. Respiratory Medicine Case Reports 34, pages 101472.
Crossref
Crossref
Jaume Bordas-Martinez, Ana Belén Llanos-González, Ramon Jodar-Masanes, Vanesa Vicens-Zygmunt, Guadalupe Bermudo, Patricio Luburich, Jordi Dorca, Maria Molina-Molina & Guillermo Suarez-Cuartin. (2021) Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. Open Respiratory Archives 3:1, pages 100080.
Crossref
Crossref